Infex Therapeutics

News

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.